Rubius_Logo.jpg
Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors
24 mai 2022 08h00 HE | Rubius Therapeutics
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
10 mai 2022 08h00 HE | Rubius Therapeutics
Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-(L)1 Refractory Disease ...
Rubius_Logo.jpg
Rubius Therapeutics to Announce First Quarter 2022 Financial Results
26 avr. 2022 08h00 HE | Rubius Therapeutics
CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create...
Rubius_Logo.jpg
Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability
08 avr. 2022 13h00 HE | Rubius Therapeutics
Best Responses Include Partial Responses in Certain Patients with Non-Small Cell Lung Cancer, Metastatic Anal Cancer and Metastatic Uveal Melanoma with No Treatment-Related Grade 3/4 Adverse Events or...
Rubius_Logo.jpg
Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
07 avr. 2022 08h00 HE | Rubius Therapeutics
CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create...
Rubius_Logo.jpg
Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American Association of Cancer Research Annual Meeting
08 mars 2022 16h30 HE | Rubius Therapeutics
Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 in Advanced Solid Tumors to be Presented in a Poster at the American Association of Cancer Research Annual Meeting on Tuesday, April...
Rubius_Logo.jpg
Rubius Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
25 févr. 2022 08h00 HE | Rubius Therapeutics
First Patient Dosed in Phase 1/2 Clinical Trial of RTX-224 in Patients with Certain Advanced Solid Tumors in January 2022Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors Continues...
Rubius_Logo.jpg
Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results
14 févr. 2022 16h15 HE | Rubius Therapeutics
CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022
01 févr. 2022 08h00 HE | Rubius Therapeutics
CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an...
Rubius_Logo.jpg
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors
13 janv. 2022 08h00 HE | Rubius Therapeutics
CAMBRIDGE, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an...